GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Antares Pharma Inc (NAS:ATRS) » Definitions » Degree of Financial Leverage

Antares Pharma (Antares Pharma) Degree of Financial Leverage : 0.00 (As of Mar. 2022)


View and export this data going back to 1996. Start your Free Trial

What is Antares Pharma Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Antares Pharma's Degree of Financial Leverage for the quarter that ended in Mar. 2022 was 0.00. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Antares Pharma's Degree of Financial Leverage or its related term are showing as below:

ATRS's Degree of Financial Leverage is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.99
* Ranked among companies with meaningful Degree of Financial Leverage only.

Antares Pharma Degree of Financial Leverage Historical Data

The historical data trend for Antares Pharma's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antares Pharma Degree of Financial Leverage Chart

Antares Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Antares Pharma Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Antares Pharma's Degree of Financial Leverage

For the Medical Instruments & Supplies subindustry, Antares Pharma's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antares Pharma's Degree of Financial Leverage Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Antares Pharma's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Antares Pharma's Degree of Financial Leverage falls into.



Antares Pharma Degree of Financial Leverage Calculation

Antares Pharma's Degree of Financial Leverage for the quarter that ended in Mar. 2022 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( 0.24 (Mar. 2022) / 0.36 (Mar. 2021) - 1 )/( 57.573 (Mar. 2022) / 20.348 (Mar. 2021) - 1 )
=-0.3333/1.8294
=-0.18***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Antares Pharma  (NAS:ATRS) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Antares Pharma Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Antares Pharma's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Antares Pharma (Antares Pharma) Business Description

Traded in Other Exchanges
N/A
Address
100 Princeton South, Suite 300, Ewing, NJ, USA, 08628
Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.
Executives
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Carmen B Volkart director C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Peter C Richardson officer: See Remarks 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Fred M Powell officer: Executive Vice President & CFO C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Thomas J Garrity director
Roche Robert P Jr director 41 MOORES ROAD FRAZER PA 19355
Leonard S Jacob director C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022
Peter J Graham officer: See Remarks 315 E. 72ND ST., APT 5E, NEW YORK NY 10021
Peter Greenleaf director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anton Gueth director
Robert F Apple director, officer: President & CEO C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422
Marvin Samson director
Jacques Gonella director C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341
James Patrick Tursi officer: EVP, Chief Medical Officer 106 ASHLEY COURT, MOORESTOWN NJ 08057
Keith E Muckenhirn officer: VP/Controller & Interim CFO C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447